Cargando…

State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus

OBJECTIVE: Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently proposed new guidelines to assess and manage ASCVD event risk specifically in LE. Here, we examined curren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Megan, Feng, Rui, Werth, Victoria P, Williams, Kevin Jon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Cutaneous Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445381/ https://www.ncbi.nlm.nih.gov/pubmed/37604650 http://dx.doi.org/10.1136/lupus-2023-000908

Ejemplares similares

Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need
por: Guo, Lisa N, et al.
Publicado: (2021)

Cutaneous lupus concerns from the patient perspective: a qualitative study
por: Yan, Daisy, et al.
Publicado: (2021)

Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus
por: Nanes, Benjamin A, et al.
Publicado: (2020)

Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
por: Izmirly, Peter, et al.
Publicado: (2019)

Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China
por: Jin, Hui, et al.
Publicado: (2023)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis
por: Drenkard, Cristina, et al.
Publicado: (2022)

Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
por: Keyes, Emily, et al.
Publicado: (2021)

Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE
por: Xie, Han, et al.
Publicado: (2023)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus
por: You, Hanxiao, et al.
Publicado: (2023)

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
por: Yazdany, Jinoos, et al.
Publicado: (2020)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
por: Elefante, Elena, et al.
Publicado: (2020)

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
por: Mertz, Philippe, et al.
Publicado: (2022)

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
por: Wang, Huijing, et al.
Publicado: (2022)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Giaglis, Stavros, et al.
Publicado: (2021)

Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
por: Floris, Alberto, et al.
Publicado: (2022)

Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective
por: Pons-Estel, Guillermo J, et al.
Publicado: (2020)

The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial
por: Keramiotou, Kyriaki, et al.
Publicado: (2020)

Increased risk of congenital malformations in offspring born to women with systemic lupus erythematosus in South Korea: a nationwide population-based study
por: Jung, Young Mi, et al.
Publicado: (2023)

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
por: Tani, Chiara, et al.
Publicado: (2019)

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
por: Zhang, Fengchun, et al.
Publicado: (2022)

Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset
por: Alves, Pedro, et al.
Publicado: (2021)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study
por: Gupta, Varsha, et al.
Publicado: (2018)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus
por: AlE'ed, Ashwaq, et al.
Publicado: (2018)

Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01
por: Kawasaki, Aya, et al.
Publicado: (2023)

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
por: Calabrese, Cassandra, et al.
Publicado: (2023)

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sspqlnpm2nu0qm652vmrp0pcft